Healthcare Professionals' Perceptions About Medical Cannabis in Greece: A Qualitative Study
- PMID: 40276093
- PMCID: PMC12015895
- DOI: 10.3390/jmahp13020013
Healthcare Professionals' Perceptions About Medical Cannabis in Greece: A Qualitative Study
Abstract
Background: Medical cannabis continues to generate interest as a potential therapeutic option, yet its acceptance in clinical practice faces challenges, including regulatory barriers, social stigma, and gaps in scientific evidence.
Methods: This study explores the perspectives of Greek medical doctors and pharmacists on medical cannabis-key stakeholders in its clinical application-through semi-structured interviews with 12 participants from each profession.
Results: Medical doctors and pharmacists expressed a range of views on medical cannabis, with many acknowledging its potential while emphasizing the need for rigorous, disease-specific research. Medical doctors highlighted the lack of consistent clinical trials, concerns about drug interactions, and the fine line between medical use and misuse. Pharmacists echoed these concerns, citing regulatory inconsistencies and the need for standardized dosing. Both groups agreed that social stigma and misinformation hinder cannabis adoption, advocating for targeted education and transparent research communication. Participants indicated that regulatory barriers also pose challenges, with calls for harmonized policies and phased market entry approaches. Effective communication strategies, including digital outreach and clear messaging, were suggested to differentiate medical cannabis from recreational use and improve trust among healthcare providers and patients. Participants also highlighted the urgent need for collaboration between policymakers, researchers, and healthcare professionals to establish medical cannabis as a credible therapeutic option.
Conclusion: The insights gained provide actionable recommendations to bridge existing gaps and emphasize the need for a responsible, evidence-based approach to the acceptance of medical cannabis as a therapeutic option.
Keywords: communication strategies; health policy; market access; medical cannabis; regulatory barriers; scientific evidence; social stigma.
© 2025 by the authors.
Conflict of interest statement
Conflicts of InterestThe authors declare no conflicts of interest.
Similar articles
-
Assessing the Market Readiness for Medical Cannabis in Greece: A Qualitative Study of Patient Perspectives.Medicines (Basel). 2025 May 9;12(2):12. doi: 10.3390/medicines12020012. Medicines (Basel). 2025. PMID: 40407604 Free PMC article.
-
Perspectives on formation of medical cannabis market in Ukraine based on holistic approach.J Cannabis Res. 2020 Oct 2;2(1):33. doi: 10.1186/s42238-020-00044-y. J Cannabis Res. 2020. PMID: 33526139 Free PMC article.
-
Enhancing medication management of older adults in Qatar: healthcare professionals' perspectives on challenges, barriers and enabling solutions.Ther Adv Drug Saf. 2024 Oct 7;15:20420986241272846. doi: 10.1177/20420986241272846. eCollection 2024. Ther Adv Drug Saf. 2024. PMID: 39421007 Free PMC article.
-
A systematic review of medical students' and professionals' attitudes and knowledge regarding medical cannabis.J Cannabis Res. 2021 Oct 12;3(1):47. doi: 10.1186/s42238-021-00100-1. J Cannabis Res. 2021. PMID: 34641976 Free PMC article. Review.
-
European Stakeholder Learnings Regarding Biosimilars: Part I-Improving Biosimilar Understanding and Adoption.BioDrugs. 2020 Dec;34(6):783-796. doi: 10.1007/s40259-020-00452-9. BioDrugs. 2020. PMID: 33141421 Free PMC article. Review.
References
-
- Grimison P., Mersiades A., Kirby A., Tognela A., Olver I., Morton R.L., Haber P., Walsh A., Lee Y., Abdi E., et al. Oral cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: Final results of a randomized, placebo-controlled, phase II/III trial. J. Clin. Oncol. 2024;42:4040–4050. - PMC - PubMed
-
- Jeddi H.M., Busse J.W., Sadeghirad B., Levine M., Zoratti M.J., Wang L., Noori A., Couban R.J., Tarride J.E. Cannabis for medical use versus opioids for chronic non-cancer pain: A systematic review and network meta-analysis of randomised clinical trials. BMJ Open. 2024;14:e068182. doi: 10.1136/bmjopen-2022-068182. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources